# Eikon Therapeutics, Inc. (EIKN)

> Source: Nexqual · https://nexqual.com/EIKN · data as of 2026-11-09 21:00 UTC · cite as "Nexqual, Eikon Therapeutics, Inc. (EIKN), nexqual.com/EIKN" · informational, not investment advice.

## What changed for EIKN since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 9, 2026).

- In the latest 13F period (Q2 2026), 1 of 80 superinvestors tracked by Nexqual hold EIKN; 1 opened new positions, 0 added and 0 reduced.
- Analyst actions on EIKN in the last 120 days: 2 (0 upgrades or target raises, 1 downgrades or target cuts); most recent HC Wainwright & Co., Oct 16, 2026.

**Price:** USD 5.87 (-0.51% on the day) · last close of Nov 9, 2026; US market pre market, not a live price. Prev close 5.9 · day 5.62–6.04 · 52w 5.01–17.4 · market cap $318M · NMS

## Key facts
- 1 of 80 tracked superinvestors hold EIKN (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $1.0M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 24.33 (range 4–32).
- Total return with dividends: 1Y -60.9% vs S&P 500 +11.7%; 5Y -59.5% vs S&P 500 +72.2%.
- Next earnings: 2026-11-12, EPS estimate USD -1.6, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: EIKN paid no cash dividend in the last five years.
- Short interest: 15.62% of float (as of 2026-10-15), 9.8 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.7x · FCF yield -90.14% · Earnings yield -108.45%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold EIKN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | <0.01% | $466K | New position |

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $1.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-03 | Column Group Iv Gp, Lp |  | 89,200 | $1.0M | 11.56 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 24.33 (low 4, high 32).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | HC Wainwright & Co. | Initiated | Buy | $23 |
| 2026-08-14 | Wedbush | Target lowered | Underperform | $5 → $4 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-02-05) | 5Y (from 2026-02-02) |
|---|---|---|
| Total return | -60.9% | -59.5% |
| S&P 500 (SPY) | +11.7% | +72.2% |
| Per year | — | — |
| Volatility (annualized) | 94.6% | 93.6% |
| Max drawdown | -67.3% (Feb 2026→Oct 2026) | -64.7% (Feb 2026→Oct 2026) |

## Dividends
EIKN paid no cash dividend in the last five years.

## Short interest
6,370,634 shares sold short, 15.62% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 5,452,560 shares (+16.8%). Days to cover: 9.8 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 107.1 +7.85% · ORKA (Oruka Therapeutics, Inc.) USD 104.56 +1.65% · ARWR (Arrowhead Pharmaceuticals, Inc.) USD 49.24 -15.34% · AXSM (Axsome Therapeutics, Inc.) USD 133.96 +1.20% · IMVT (Immunovant, Inc.) USD 35.15 +15.13% · CAI (Caris Life Sciences, Inc.) USD 25.57 +1.35%

## More
Full page: https://nexqual.com/EIKN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in EIKN's own 10-K filed 2026-03-30 (https://www.sec.gov/Archives/edgar/data/1861123/000119312526130395/eikn_form_10-k_2025.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | MSD International Business | "We have entered into Clinical Trial Collaboration and Supply Agreements, or the MSD Agreements, with MSD International Business GmbH, or MSD, for three separate studies: (i) the Phase 2/3 registrational study of EIK1001 …" |
| Partner | Superb Wisdom | "We in-licensed EIK1001 from Seven and Eight Biotherapeutics Corp. pursuant to an Exclusive Collaboration Agreement with Seven and Eight Biotherapeutics Corp. and related entities, collectively known as Seven and Eight, a…" |
| Partner | Seven and Eight Biotherapeutics | "We in-licensed EIK1001 from Seven and Eight Biotherapeutics Corp. pursuant to an Exclusive Collaboration Agreement with Seven and Eight Biotherapeutics Corp. and related entities, collectively known as Seven and Eight, a…" |
| Partner | Catalyst4 | "On June 7, 2024, we entered into a Collaboration Agreement, or the Catalyst4 Agreement, with Catalyst4, Inc., or Catalyst4, and The Column Group-Neuro, LP, or TCG." |
| Partner | Merck (MRK) | "Perlmutter and Baynes previously collaborated with our current Chief Business Officer, Benjamin Thorner, during their time at both Amgen and Merck to identify, evaluate, and acquire or in-license important medicines." |
| Partner | VERACYTE, INC. (VCYT) | "At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions." |
| Partner | ASTRAZENECA PLC (AZN) | "At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions." |
| Partner | Johnson & Johnson (JNJ) | "At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions." |

## Company outlook (8-K filed 2026-08-13)

- "Approximately 30 PARPi-na&iuml;ve, HER2-negative breast cancer patients are expected to be enrolled at each dose level."
- "Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling. • Eikon expects to submit an investigational new drug application (IND) for EIK1006 by the end of 2026."
- "DRAFT • EIK1004: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at ESMO. • EIK1005: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at the ESMO Congress 2026. • EIK1006: Expects to submit an IND by the end of 2026."
- "Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.60 | $-1.56 | −$0.05 | $0 | 5 |
| Next quarter (ends 2026-12-31) | $-1.61 | $-1.54 | −$0.08 | $0 | 5 |
| Current fiscal year (ends 2026-12-31) | $-6.58 | $-6.35 | −$0.23 | $0 | 6 |
| Next fiscal year (ends 2027-12-31) | $-6.69 | $-6.19 | −$0.51 | $0 | 6 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.63 | −$1.46 | Miss −11.6% | — |
| — | Quarter ended Mar 31, 2026 | −$2.46 | −$1.22 | Miss −101.6% | — |
| — | Quarter ended Dec 31, 2025 | −$26.23 | −$17.75 | Miss −47.8% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-26 | 8-K | Regulation FD disclosure; Other material event — “On October 26, 2026, the Company presented updated data from its TeLuRide-005 trial of EIK1001 at the 2026 ESMO Congress, detailed below. EIK1001 Clinical Update: Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced non-small cell lung cancer (NSCLC) demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile…” | https://www.sec.gov/Archives/edgar/data/1861123/000119312526430860/0001193125-26-430860-index.htm |
| 2026-10-23 | 8-K | Regulation FD disclosure; Other material event — “On October 23, 2026, the Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress, detailed below. EIK1003 Clinical Update: Updated data from EIK1003-001 demonstrate that highly selective non-brain-penetrant PARP1 inhibitor EIK1003 as monotherapy (Cohort 1A) was generally well-tolerated across multiple dose levels. In Cohort 1B, EIK1003 in combination with the novel hormonal agent abiraterone is observed to have a…” | https://www.sec.gov/Archives/edgar/data/1861123/000119312526429549/0001193125-26-429549-index.htm |
| 2026-10-07 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 10.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1861123/000031506626002331/0000315066-26-002331-index.htm |
| 2026-10-02 | Schedule 13G/A | Abu Dhabi Investment Authority, Platinum Falcon B 2018 RSC Limited: 2.1% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1861123/000110465926113112/0001104659-26-113112-index.htm |
| 2026-08-14 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/0001193125-26-349936-index.htm |
| 2026-08-13 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1861123/000119312526349185/0001193125-26-349185-index.htm |
| 2026-08-13 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/0001193125-26-349154-index.htm |
| 2026-08-06 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 9.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1861123/000031506626001987/0000315066-26-001987-index.htm |
| 2026-08-03 | 8-K | Director or executive officer change, or pay arrangement — “Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the "Company"). Dr. Chen's and Mr. Wolfe's resignations were not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.” | https://www.sec.gov/Archives/edgar/data/1861123/000119312526330710/0001193125-26-330710-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.